Investigators sought to determine the safety and efficacy of novel oral anticoagulants to treat patients with chronic kidney disease, particularly with regard to cardiovascular outcomes.
For patients with mild-to-moderate Alzheimer disease, treatment with nilvadipine lowers systolic blood pressure and increases cerebral blood flow (CBF) in the hippocampus.
Dynamic cerebral autoregulation increased six hours after RIPC, lasts for at least 24 hours.
Patients with hypertension with progression of periventricular white matter hyperintensities have an increased risk for incident mild cognitive impairment.
An artificial intelligence system can diagnose and classify intracranial hemorrhage.
Systemic vascular health measured as a composite of recent cardiovascular and metabolic chronic conditions was associated with medial temporal lobe thinning, widespread cerebral hypoperfusion, and poor microstructural integrity.
Culturally tailored, skills-based strategies may be an important alternative to knowledge-focused approaches in achieving sustained vascular risk reduction and addressing racial/ethnic stroke disparities.
The investigators of this study did not compare pre- or post-hemorrhage data, precluding their ability to determine the applicability of the findings for improving clinical practice.
In older patients, conventional hemodialysis induces a reduction in cerebral blood flow.
Somatic activating KRAS mutations are often found in patients with arteriovenous malformations of the brain.